AG
MDGL icon

Algert Global’s Madrigal Pharmaceuticals MDGL Stock Holding History

Algert Global’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Sell
3,200
-4,960
-61% -$2.54M 0.02% 879
2026
Q1 		$4.27M Sell
8,160
-810
-9% -$387K 0.06% 485
2025
Q4 		$5.22M Buy
8,970
+940
+12% +$480K 0.08% 419
2025
Q3 		$3.68M Sell
8,030
-1,500
-16% -$560K 0.06% 494
2025
Q2 		$2.88M Sell
9,530
-240
-2% -$71.5K 0.06% 510
2025
Q1 		$3.24M Hold
9,770
– – 0.08% 430
2024
Q4 		$3.01M Buy
+9,770
New +$2.75M 0.07% 466
2024
Q3 		– Sell
-1,269
Closed -$356K – 1416
2024
Q2 		$356K Buy
+1,269
New +$302K 0.01% 1046
2023
Q3 		– Sell
-7,411
Closed -$1.71M – 1195
2023
Q2 		$1.71M Sell
7,411
-2,456
-25% -$665K 0.07% 446
2023
Q1 		$2.39M Buy
9,867
+1,217
+14% +$332K 0.11% 282
2022
Q4 		$2.51M Sell
8,650
-590
-6% -$57.7K 0.14% 222
2022
Q3 		$601K Buy
9,240
+4,417
+92% +$307K 0.04% 745
2022
Q2 		$345K Hold
4,823
– – 0.03% 880
2022
Q1 		$473K Sell
4,823
-586
-11% -$49.4K 0.03% 833
2021
Q4 		$458K Buy
+5,409
New +$444K 0.06% 569

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Algert Global's MDGL Position: Q2 2026 in Review

Algert Global reduced its Madrigal Pharmaceuticals (MDGL) stake by 61% in Q2 2026, selling an estimated $2.54M and leaving 3,200 shares worth $1.72M. The position accounts for 0.02% of the portfolio, ranked #879.

Algert Global first reported a position in MDGL in Q4 2021 and has held it in 15 quarters since. The position peaked at $5.22M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Algert Global held 3,200 shares of Madrigal Pharmaceuticals worth $1.72M as of Q2 2026.
  • Algert Global sold 4,960 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.54M.
  • Madrigal Pharmaceuticals made up 0.02% of Algert Global's portfolio in Q2 2026, its #879 holding.
  • Algert Global first reported a position in Madrigal Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Algert Global's Madrigal Pharmaceuticals position peaked at $5.22M in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.